Galapagos NV

Galapagos has had a change of heart on plans to spin out a company this year, citing ‘regulatory and market developments.’ Less than a month ago, Galapagos unveiled ex-AbbVie and Neumora leader Henry

Galapagos revealed its second leadership transition in as many weeks on 22 April, reporting that CEO Paul Stoffels plans to retire from the company upon the appointment of a new chief executive, who w

Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do

After years of declining investor confidence in its business model, Galapagos is to start afresh by splitting in two and resetting its failed in-licensing deal with Gilead . The Belgium-based biote